Drug lookup
Drug reference

Tolterodine

Antimuscarinic · Urinary antispasmodic

Also known as tolterodine tartrate

AntimuscarinicUrinary antispasmodic
CDSCO approved
EXCRETION
not curated
INTERACTIONS
4 major
SEVERE in our sources
PREGNANCY
not curated
Top interactionssee all 12
  • Potassium ChlorideSevereDatabaseDDInter
  • Potassium CitrateSevereDatabaseDDInter
  • TopiramateSevereDatabaseDDInter
  • ZonisamideSevereDatabaseDDInter

Mechanism

Tolterodine is an anticholinergic drug, exerting antimuscarinic effects. Its use contributes to the overall anticholinergic burden, which can lead to cognitive impairment.

Indications

Urgency incontinence (considered after bladder training has been trialled, especially when frequency is a problem and symptoms persist)Overactive bladderOveractive bladder with urinary frequency and urgency

Dosing

Adult
Lower initial doses recommended for patients with low CYP2D6 activity
Hepatic adjustment
Dose should be halved in patients receiving CYP3A4 inhibitors (erythromycin, ketoconazole, etc.)
Geriatric
Treatment should be reviewed every 6 months for women over 75 years of age. Clinicians should consider total anticholinergic load, coexisting conditions (such as cognitive impairment or poor bladder emptying), and the risk of side-effects when prescribing anticholinergic medicine. Refer to 'Dementia p. 315' when prescribing in patients with dementia.

Pharmacokinetics

Bioavailability
EM: 26 ± 18%; PM: 91 ± 40%
Protein binding
T: 96.3%; 5-HM: 64%
Metabolism
Metabolized by CYP2D6 to 5-hydroxymethyltolterodine (an active metabolite)
Excretion
EM: Negligible; PM: <2.5%

Contraindications

  • Cognitive impairment
  • Poor bladder emptying
  • When anticholinergic treatment is contra-indicated (mirabegron may be considered as an alternative in such cases)

Side effects

Common
Cognitive impairmentXerostomiaBlurred visionConstipationGastrointestinal discomfortDrowsinessDizzinessConfusionLess likely to cause dryness of mouth and other anticholinergic side effects compared to non-selective agents

Drug interactions

Potassium Chloride
Severe
Database

.

Source: DDInter

Potassium Citrate
Severe
Database

Clinical effect not specified

Source: DDInter

Topiramate
Severe
Database

.

Source: DDInter

Zonisamide
Severe
Database

Clinical effect not specified

Source: DDInter

Lopinavir
Moderate
Textbook

Increased plasma levels and effects of tolterodine.

The dose of tolterodine should be halved in patients receiving CYP3A4 inhibitors.

Source: KDT 7e · p118

Aprepitant
Moderate
Database

Increased plasma levels and effects of tolterodine.

The dose of tolterodine should be halved in patients receiving CYP3A4 inhibitors.

Source: DDInter

Ciprofloxacin
Moderate
Database

Increased plasma levels and effects of tolterodine.

The dose of tolterodine should be halved in patients receiving CYP3A4 inhibitors.

Source: DDInter

Clarithromycin
Moderate
Database

Increased plasma levels and effects of tolterodine.

The dose of tolterodine should be halved in patients receiving CYP3A4 inhibitors.

Source: DDInter

Cobicistat
Moderate
Database

Increased plasma levels and effects of tolterodine.

The dose of tolterodine should be halved in patients receiving CYP3A4 inhibitors.

Source: DDInter

Diltiazem
Moderate
Database

Increased plasma levels and effects of tolterodine.

The dose of tolterodine should be halved in patients receiving CYP3A4 inhibitors.

Source: DDInter

Erythromycin
Moderate
Database

Increased plasma levels and effects of tolterodine.

The dose of tolterodine should be halved in patients receiving CYP3A4 inhibitors.

Source: DDInter

Fluconazole
Moderate
Database

Increased plasma levels and effects of tolterodine.

The dose of tolterodine should be halved in patients receiving CYP3A4 inhibitors.

Source: DDInter

Related guidelines

Other Antimuscarinic drugs

Ask House about Tolterodine

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team